Core Viewpoint - The company, Ying's Holdings, is facing significant challenges in its IPO process, including delays in responding to regulatory inquiries and ongoing issues related to trademark disputes, high marketing costs, and insufficient R&D investment, which are negatively impacting its market reputation and financial performance [1][2]. Financial Performance - Ying's Holdings reported revenue growth from 1.296 billion yuan in 2022 to 1.974 billion yuan in 2024, but the growth rate has significantly slowed, dropping from 37.35% in 2022 to 12.35% in 2024 [3]. - The net profit showed a decline, with figures of 117 million yuan in 2022, 220 million yuan in 2023, and a decrease to 211 million yuan in 2024, resulting in a negative growth rate of -4.37% in 2024 after two years of substantial increases [3]. Expense Analysis - In 2024, the company's sales expenses reached 721 million yuan, accounting for 36.53% of total revenue, which is higher than the average of comparable companies [4]. - R&D expenses were significantly lower, with only 17.15 million yuan in 2024, indicating a lack of investment in innovation compared to sales expenses [5]. Regulatory Challenges - The company has faced scrutiny from the North Exchange regarding the high sales expense ratio and the adequacy of its marketing expenditures, which raises concerns about the sustainability of its business model [5]. - Ying's Holdings has been required to clarify the necessity and feasibility of its fundraising projects, which include significant investments in production and brand development [8]. Product Quality Issues - The company has been repeatedly criticized for quality issues, particularly with its baby food products, which have been reported to contain foreign objects, leading to consumer complaints and damaging its reputation [6][7]. - The frequency of complaints regarding product safety has raised doubts about the company's commitment to maintaining quality standards in its offerings [7].

Core Viewpoint - Ying's Holdings Group Co., Ltd. has submitted an IPO application to the Beijing Stock Exchange, aiming to raise 334 million yuan for various projects, despite showing signs of declining performance in recent years [1][3]. Financial Performance - Ying's Holdings reported revenue of 1.296 billion yuan in 2022, 1.758 billion yuan in 2023, and 1.974 billion yuan in 2024, with year-on-year growth rates of 37.35%, 35.67%, and 12.29% respectively [3]. - The company's net profit attributable to shareholders was 117 million yuan in 2022, 220 million yuan in 2023, and 211 million yuan in 2024, with growth rates of 64.91%, 87.67%, and a decline of 4.36% [3]. - In the first quarter of 2025, the company achieved a revenue of 540 million yuan, a year-on-year increase of 12.29%, and a net profit of 79 million yuan, up 4.73% [3]. Business Segmentation - In 2024, the revenue from infant complementary food reached 1.524 billion yuan, growing by 5.48% and accounting for 77% of total revenue [5]. - Revenue from infant hygiene products was 340 million yuan, up 31.28%, making up 17% of total revenue [5]. - Revenue from children's food was 95 million yuan, showing a significant increase of 159.7%, representing 5% of total revenue [5]. Production and Quality Control - Ying's Holdings relies heavily on contract manufacturing for its products, with only rice flour produced in-house, leading to potential quality control issues [2][10]. - The company has faced consumer complaints regarding product quality, with issues reported on platforms like Black Cat Complaints and Xiaohongshu [2][10]. - The production capacity utilization rates for rice flour, diapers, and other products were 72.53%, 85.06%, and 85.73% respectively, indicating a reliance on external manufacturers for most products [11]. Marketing and R&D Expenditure - The company allocated nearly 40% of its revenue to marketing, with sales expenses increasing significantly from 454 million yuan in 2022 to 721 million yuan in 2024 [8]. - In contrast, R&D expenses were relatively low, at 6 million yuan, 9 million yuan, and 17 million yuan for the years 2022 to 2024, with R&D expense ratios of 0.43%, 0.52%, and 0.87% respectively [8].

Core Viewpoint - Ying's Holdings Group Co., Ltd. has applied for an IPO on the Beijing Stock Exchange, revealing a slowdown in revenue growth and a heavy reliance on its core infant food business [1][2]. Financial Performance - Revenue projections for 2022, 2023, and 2024 are 1.3 billion, 1.76 billion, and 1.97 billion yuan, respectively, with net profits of 120 million, 220 million, and 210 million yuan [1][2]. - Revenue growth rates are 37.4%, 35.7%, and 12.3% for the respective years, while net profit growth rates are 64.9%, 87.7%, and -4.4% [2]. - In Q1 2025, revenue increased by 12.3% to 540 million yuan, and net profit rose by 5.4% to 81.17 million yuan [2]. Business Model - The infant food business accounts for 79.75%, 82.35%, and 77.4% of total revenue from 2022 to 2024, with a stable gross margin of around 61% [2]. - The company has a high reliance on the OEM model, with revenues from contract manufacturing at 531 million, 696 million, and 540 million yuan for 2021, 2022, and the first half of 2023, respectively [3]. Marketing and R&D Expenses - Sales expense ratios are significantly high at 35.04%, 34.26%, and 36.53% from 2022 to 2024, exceeding the industry average of 27.75% [3]. - In 2024, sales expenses reached 720 million yuan, with over half attributed to e-commerce platform promotion and usage fees [3]. - R&D expenditures are low, with amounts of 5.53 million, 9.21 million, and 17.15 million yuan from 2022 to 2024, resulting in R&D expense ratios below 1% [3].

Core Viewpoint - Ying's Holdings, a leading company in the infant food sector, has applied for an IPO on the Beijing Stock Exchange, aiming to raise funds for industrial base construction, brand development, and project promotion, while facing challenges related to quality control and marketing versus R&D investment [2][4][10]. Group 1: Company Overview - Ying's Holdings was established in 2014, focusing on infant food, with brands including "Ying's" and "Shu Bi Qi," and has ranked first in sales in the infant food market for three consecutive years [3][4]. - The company’s revenue from infant food has been stable, contributing approximately 79.75% to 82.35% of total revenue from 2022 to 2024, with a gross margin around 61% [6][4]. Group 2: Financial Performance - Revenue figures for Ying's Holdings from 2022 to 2024 were 1.3 billion, 1.76 billion, and 1.97 billion respectively, with year-on-year growth rates of 37.4%, 35.7%, and 12.3% [4]. - Net profit for the same period was 120 million, 220 million, and 210 million, with growth rates of 64.9%, 87.7%, and -4.4% [4]. - In Q1 2025, revenue grew by 12.3% to 540 million, and net profit increased by 5.4% to 81.17 million [4]. Group 3: Market Competition - The infant food market in China is becoming increasingly competitive, with international brands like Heinz and new entrants leveraging online channels to gain market share [3][4]. - Ying's Holdings faces challenges from both established international brands and emerging local brands, which are rapidly capturing market share [3][4]. Group 4: IPO and Fund Utilization - The company plans to raise 334 million for various projects, including 71.69 million for the Hunan Ying's maternity and infant industry base, 48.20 million for instant nutrition porridge production, and 94.05 million for brand promotion [4][5]. - Ying's Holdings is actively responding to inquiries from the Beijing Stock Exchange regarding its IPO application [4]. Group 5: Quality Control and Production Model - The company relies on a mix of self-production and outsourcing, with approximately 63.53% of revenue from outsourced production in 2023 [6][7]. - Quality control issues have arisen from the reliance on third-party manufacturers, leading to regulatory inquiries and consumer complaints [7][8]. Group 6: Marketing and R&D Investment - Ying's Holdings has a high marketing expense ratio, with sales expense rates of 35.04%, 34.26%, and 36.53% from 2022 to 2024, significantly above the industry average of 27.75% [10][11]. - R&D investment remains low, with R&D expense rates of 0.43%, 0.52%, and 0.87% during the same period, below the industry average of 2.03% [10][11].